Introducing Shire
- A UK success story
- Global company, UK headquarters
- Employs around 2,400 worldwide, 350 in UK
- Invests considerable revenues in R&D each year
- Expertise in attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases
 Founded in 1986, Shire is a British pharmaceutical industry success story. Headquartered in Basingstoke in Hampshire, we currently employ around 2,400 people with 350 jobs being in the UK. Shire is the third largest pharmaceutical company in the UK and operates worldwide with active participation in countries in Europe and North America. Rapidly growing and internationally emerging, our approach is firmly based on the development and marketing of treatments prescribed by specialist doctors.
Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. In the UK, our treatments include REMINYL® (galantamine hydrobromide) to treat Alzheimer's disease, Calcichew D3® and CALCICHEW D3 FORTE® for osteoporosis, REPLAGALTM (agalsidase alfa) for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease ( α -galactosidase A deficiency), SOLARAZE® (dicolfenac sodium 3%) for actinic keratosis (pre-cancerous skin lesions) and XAGRID® (anagrelide hydrochloride) for the reduction of elevated platelet counts in at-risk essential thrombocythaemia patients. In addition, in the United States we market ADDERALL XR® (mixed amphetamine salts), DAYTRANA® (methylphenidate transdermal system) for attention deficit hyperactivity disorder and ELAPRASETM (idursulfase) for the long-term treatment of patients with Hunter syndrome (Mucopolysaccharidosis II).
The world's most prescribed HIV treatment, 3TC, a registered trademark of GSK, was discovered by Shire Biochem and is licensed to GSK.
 In addition to developing and marketing drug therapies, Shire also takes an active interest in policy development both in the broader NHS and in the disease areas where we have a particular specialism. As well as inputting directly into the various NHS reform processes, we are also involved in various initiatives in the UK to help to improve the standard of care received by patients at local level especially in osteoporosis, old age psychiatry and skin disease. This includes working with the Modernisation Agency and NHS collaboratives to help to deliver, as cheaply and effectively as possible, the target that all ambulatory patients residing in residential homes should be prescribed calcium and vitamin D.
To view our 2005 online annual review and summary financial statement please click here.
|
